Parkinson disease: Managing a complex, progressive disease at all stages

Cleveland Clinic Journal of Medicine

Volumn 74, Issue 5, 2007, Pages 313-328

  Giroux, Monique L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249279175     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.5.313     Document Type: Review

References (70)

1. Rajput A, Offord K, Beard C, Kurland L. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16:278-282.
2. Mayeux R, Denaro J, Hemenegildo, N, et al. A population-based investigation of Parkinson's disease. Arch Neurol 1992; 49:494-497.
3. Arevalo G, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Mov Disord 1997; 12:277-284.
4. Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol 2005; 18:363-369.
5. Forno L. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55:259-272.
6. Paulson H, Stern M. Clinical Manifestations of Parkinson's Disease. New York: McGraw Hill; 1997.
7. Braak B, Ghebremedhim E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318:121-134.
8. Lai B, Marion S, Teschke K, Tsui J. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat Disord 2002; 8:297-309.
9. Checkoway H, Powers K, Smith-Weller T, Franklin G, Longstreth W, Swanson P. Parkinson's disease risk associated with cigarette smoking, alcohol consumption and caffeine intake. Am J Epidemiol 2002; 155:732-738.
10. Allam M, Campbell M, Hofman A, Del Castillo A, Navajas R. Smoking and Parkinson's disease: systemic review or prospective studies. Mov Disord 2004; 19:614-621.
11. Ross G, Abbott R, Petrovich H, et al. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA 2000; 284:1378-1379.
12. Chen H, Zhang S, Schwarzschild M, Hernan M, Ascherio A. Physical activity and the risk of Parkinson's disease. Neurology 2005; 64:4664-4669.
13. Rocco W, McDonnell S, Strain K, et al. Familial aggregation of Parkinson's disease: the Mayo Clinic family study. Ann Neurol 2004; 56:495-502.
14. Tanner C, Ottman R, Goldman S, et al. Parkinson disease in twins. An etiologic study. JAMA 1999; 281:341-346.
15. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442.
16. Gelb D, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999; 56:33-39.
17. Deuschl G. Differential diagnosis of tremor. J Neural Transm 1998; 56:211-220.
18. Hubble JP. Drug-induced Parkinsonism. New York: McGraw-Hill; 2004.
19. Rochaon P, Stukel T, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005; 165:1882-1888.
20. Adler CH. Parkinson's disease and parkinsonian syndromes: differential diagnosis of Parkinson's disease. Med Clin North Am 1999; 83:2.
21. Christine CW, Aminoff MJ. Clinical differentiation of parkinsonian syndromes: prognosis and therapeutic relevance. Am J Med 2004; 117:412-419.
22. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W. Practice parameter: diagnosis and prognosis of new onset Parkinson's disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:968-975.
23. Muller J, Wenning G, Jellinger K, McKee A, Poewe W, Litvan I. Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. Neurology 2000; 55:888-891.
24. Louis E, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson's disease. Arch Neurol 1997; 54:260-264.
25. Witjas T, Kaplan E, Azulay J, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59:408-413.
26. Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord 2005; 20(suppl 11):S23-S29.
27. Shulman L, Taback R, Bean J, Weiner W. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001; 16:507-510.
28. Hillen M, Sage J. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996; 47:1180-1183.
29. Weintraub D, Moberg P, Duda J, Katz I, Stern M. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatric Soc 2004; 52:784-788.
30. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995; 52:695-701.
31. McKeith I, Dickson D, Emre M, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005; 65:1863-1872.
32. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351:2509-2518.
33. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double blind, placebo-controlled international study. Lancet 2000; 356:2031-2036.
34. Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002; 23:S89-S90.
35. Slawek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson's disease: a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat Disord Epub 2005; 11:465-468.
36. Sawabini K, Watts R. Treatment of depression in Parkinson's disease. Parkinsonism Relat Disord 2004; 10(suppl 1):S37-541.
37. Miyasaki J, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:996-1002.
38. Ward CD, Robertson D. Rehabilitation in Parkinson's disease. Rev Clin Gerontol 2003; 13:223-239.
39. Iansek R. Interdisciplinary Rehabilitation in Parkinson's Disease. Philadelphia: Lippincott Williams & Wilkins, 1999.
40. The Parkinson's Study Group. Levodopa and progression of Parkinson's disease. N Engl J Med 2004; 351:2498-2508.
41. Ahlskog JE, Muenter M. Frequency of levodopa dyskinesia and motor fluctuations as estimated from the cumulative literature. Mov Disord 2002; 16:448-458.
42. Widnell K. Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord 2005; 20(suppl 11):S17-S22.
43. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(suppl 5):S1-S88.
44. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005; 22:731-740.
45. The Parkinson's Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: 4-year randomized controlled trial. Arch Neurol 2004; 61:1044-1153.
46. Rascol O, Brooks DJ, Korczyn AD, DeDeyn PP, Clarke C, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342:1484-1491.
47. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29-38.
48. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39-46.
49. The Parkinson's Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2002; 61:561-566.
50. The Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328:176-183.
51. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50:375-382.
52. Miyasaki J, Martin W, Suchowersky O, Weiner J, Lang A. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 58:11-17.
53. The Parkinson's Study Group. Entacapone improves motor fluctuations in levodopa treated Parkinson's disease patients. Ann Neurol 1997; 42:747-755.
54. Agid Y, Ahlberg J, Burgunder JM, et al. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled tial in advanced Parkinson's disease. CNS Drugs 2005; 19:165-184.
55. Lieberman A, Olanow W, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998; 51:1057-1062.
56. Waters C, Sethi K, Hauser R, et al. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19:426-432.
57. The Parkinson's Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuation: the PRESTO study. Arch Neurol 2005; 62:241-248.
58. Dewey R, Hutton J, LeWitt P, Factor S. A randomized, double blind, placebo controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58:1385-1392.
59. Metman L, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase T. Amantadine for levodopa induced dyskinesia: a 1-year follow-up study. Arch Neurol 1999; 56:1383-1386.
60. Welter M, Houeto J, Tezenas du Montcel S, et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 2002; 125:575-583.
61. The Deep Brain Stimulation Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345:956-963.
62. Krack P, Batir A. Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349:1925-1934.
63. Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous parkinsonism. Arch Neurol 2006; 63:354-357.
64. Tsui JKC. Treatment of Dystonia in Parkinson's Disease. Philadelphia: Lipincott Williams & Wilkins; 2003.
65. Aarsland D, Larsen J, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based prospective study. J Am Geriatric Soc 2000; 48:938-942.
66. Goetz C, Stebbins G. Risk factors of nursing home placement in advanced Parkinson's disease. Neurology 1993; 43:2227-2229.
67. The Parkinson's Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340:757-763.
68. Aarsland D, Laake K, Larsen J, Janvine C. Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002; 72:708-712.
69. Vaserman M. Parkinson's disease and osteoporosis. Joint Bone Spine 2005; 72:484-488.
70. LeWitt P. Clinical trials of neuroprotection for Parkinson's disease. Neurology 2004; 63(suppl 2):S23-S31.